Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
Go back to Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 54.00 -1.28 (2.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.28 | 52 Week High | $77.12 | |||
| Open | $55.20 | 52 Week Low | $49.03 | |||
| Day High | $55.33 | P/E | 35.06 | |||
| Day Low | $53.44 | EPS | $1.54 | |||
| Volume | 31,700,384 | |||||
